Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial) for Anesthesia During Endoscopic Procedures

What this Trial Is About

Researchers are evaluating two different mixtures of propofol and etomidate anesthesia used during endoscopic procedures to determine which ratio provides more stable heart and lung function and fewer side effects. This phase 3, randomized, double-blind trial compares an admixture of propofol and etomidate at 25%/75% (P2E7) versus 75%/25% (P7E2) in adult patients undergoing these procedures. The study aims to provide clear guidance on anesthesia use in older patients or those with chronic conditions needing endoscopy. Participants receive one of two anesthesia mixtures administered during their endoscopic procedure at the Clements University Hospital endoscopy lab. Both mixtures are prepared fresh and blinded so neither patients nor clinicians know the exact ratio. Propofol and etomidate are FDA-approved drugs combined in varying ratios to assess which maintains better cardiovascular stability while minimizing adverse effects. This trial runs over an estimated 6 to 12 months. During the study, researchers monitor heart pressure, oxygen levels, use of blood pressure medications, and adverse events like nausea or emergency responses. Assessments include clinician, endoscopist, and patient evaluations of anesthesia quality. Data on recovery times and medication doses are also collected. Safety is closely followed during and after the procedure, with outcomes measured up to 30 days post-anesthesia to evaluate cardiac events and side effects.

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)